Metabolex is a company dedicated to the discovery and development of novel therapeutics for diabetes and related metabolic disorders. They recently announced the launch of a double-blind, placebo-controlled Phase 2a, proof-of-concept study for MBX-2044, an oral insulin sensitizer for the treatment of type 2 diabetes.

Metaglidasen and MBX-2044 address insulin resistance, the underlying cause of type 2 diabetes, by enhancing insulin sensitization. The currently marketed insulin sensitizers, Actos® and Avandia®, carry warnings of increased risk of congestive heart failure due to edema and cause significant weight gain, which compromises patient compliance.

Metaglidasen and MBX-2044 have been specifically designed to address the shortcomings of the currently marketed insulin sensitizer drugs. Clinical testing of metaglidasen suggests it has comparable efficacy with an improved safety profile. Now we're getting somewhere with this medical advancement stuff! A new drug that does the trick sans the undesirable side effects - attaboy, Metabolex!